

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5972488

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the NAME OF THE RECEIVING PARTY ON THE PATENT ASSIGNMENT COVER SHEET previously recorded on Reel 048972 Frame 0408. Assignor(s) hereby confirms the NAME OF THE RECEIVING PARTY IS HANGZHOU SOLIPHARMA CO., LTD.
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
XIAOHONG SHENG	02/02/2019
XIAOXIA SHENG	02/13/2019
XIAWEI JIANG	02/13/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	HANGZHOU SOLIPHARMA CO., LTD.
<b>Street Address:</b>	2B05, BUILDING 1, NO. 452, 6TH AVE.
<b>Internal Address:</b>	HANGZHOU ECONOMIC AND TECHNOLOGY DEVELOPMENT AREA
<b>City:</b>	HANGZHOU, ZHEJIANG
<b>State/Country:</b>	CHINA
<b>Postal Code:</b>	310018
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16318055
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(202) 371-2600
<b>Email:</b>	XSHEN@sternekessler.com, hbodine@sternekessler.com, ttopssecretary3@sternekessler.com
<b>Correspondent Name:</b>	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
<b>Address Line 1:</b>	1100 NEW YORK AVENUE, NW
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005
<b>ATTORNEY DOCKET NUMBER:</b>	3663.0110001
<b>NAME OF SUBMITTER:</b>	XIANFENG SHEN
<b>SIGNATURE:</b>	/Xianfeng Shen, Reg. No. 69,162/
<b>DATE SIGNED:</b>	02/20/2020

**Total Attachments: 5**

source=Assignment-Recorded-3663-0110001#page1.tif

source=Assignment-Recorded-3663-0110001#page2.tif

source=Assignment-Recorded-3663-0110001#page3.tif

source=Assignment resigned - 3663.0110001#page1.tif

source=Assignment resigned - 3663.0110001#page2.tif

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5488307

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
XIAOHONG SHENG	02/02/2019
XIAOXIA SHENG	02/13/2019
XIAWEI JIANG	02/13/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SOLIPHARMA LLC
<b>Street Address:</b>	2B05, BUILDING 1, NO. 452, 6TH AVE.
<b>Internal Address:</b>	HANGZHOU ECONOMIC AND TECHNOLOGY DEVELOPMENT AREA
<b>City:</b>	HANGZHOU, ZHEJIANG
<b>State/Country:</b>	CHINA
<b>Postal Code:</b>	310018
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16318055
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2023712600
<b>Email:</b>	kmurray@sternekessler.com, xshen@sternekessler.com, nlu@sternekessler.com
<b>Correspondent Name:</b>	STERNE, KESSLER, GOLDSTEIN AND FOX P.L.L.C.
<b>Address Line 1:</b>	1100 NEW YORK AVENUE NW
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005
<b>ATTORNEY DOCKET NUMBER:</b>	3663.0110001
<b>NAME OF SUBMITTER:</b>	XIANFENG SHEN
<b>SIGNATURE:</b>	/Xianfeng Shen, Reg. No. 69,162/
<b>DATE SIGNED:</b>	04/23/2019
<b>Total Attachments: 2</b>	
source=2019-04-22-Executed-Assignment-3663-0110001#page1.tif	
source=2019-04-22-Executed-Assignment-3663-0110001#page2.tif	

**ASSIGNMENT**

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Xiaohong SHENG, Xiaoxia SHENG and Xiawei JIANG**, hereby sell and assign to **Solipharma LLC**, a corporation formed under the laws of China, whose mailing address is 2B05, Building 1, No. 452 6th Ave., Hangzhou Economic and Technology Development Area, Hangzhou, Zhejiang, 310018 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of January 15, 2019 (also known as United States Application No. 16/318,055, which is the U.S. national phase of International Application No. PCT/CN2016/105405, International Filing Date November 11, 2016), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.




The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: <u>Feb-02-2019</u>	Signature of Inventor: <u></u> Xiaohong SHENG
Date: <u>2019.02.13</u>	Signature of Inventor: <u></u> Xiaoxia SHENG
Date: <u>2019.02.13</u>	Signature of Inventor: <u></u> Xiawei JIANG

SIGNED on behalf of the said ASSIGNEE,

Solipharma LLC

By:   
Name: Xiaoxia SHENG  
Title: CEO

Date: 2019.02.13

ASSIGNMENT

Hangzhou SoliPharma Co., Ltd. X.S. 2019-07-25

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Xiaohong SHENG, Xiaoxia SHENG and Xiawei JIANG, hereby sell and assign to SoliPharma LLC, a corporation formed under the laws of China, whose mailing address is 2B05, Building 1, No. 452 6th Ave., Hangzhou Economic and Technology Development Area, Hangzhou, Zhejiang, 310018 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world, X.S. 2019-07-31 2019.8.2

(a) in the invention(s) known as **CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of January 15, 2019 (also known as United States Application No. 16/318,055, which is the U.S. national phase of International Application No. PCT/CN2016/105405, International Filing Date November 11, 2016), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: <u>Feb-02-2019</u>	Signature of Inventor: <u>[Signature]</u> Xiaohong SHENG
Date: <u>2019.02.13</u>	Signature of Inventor: <u>[Signature]</u> Xiaoxia SHENG
Date: <u>2019.02.13</u>	Signature of Inventor: <u>[Signature]</u> Xiawei JIANG

SIGNED on behalf of the said ASSIGNEE,

*Hangzhou Solipharma Co., Ltd.*  
*X.S. 2019.2.2*

~~Solipharma LLC~~  
By: [Signature]  
Name: Xiaoxia SHENG  
Title: CEO

Date: 2019.02.13